Canget BioTekpharma, LLC (Canget) is a biotech and biopharma company, and was spun off in 2012 from Roswell Park Cancer Institute (RPCI, Buffalo, New York). Canget focuses on the development of novel, cancer-targeting anticancer agents that exhibit low toxicity to normal tissue and high efficacy to cancer.

Biotechnology

Canget BioTekpharma

Canget BioTekpharma's headquarters in Buffalo, NY, United States

John J. Seman

Alex A. Adjei

Fengzhi Li

Scott Friedman

Youcef M. Rustum

Martin K. Casstevens

Carl Porter

Ravindra K Pandey

Nathan R. Wall

Lili Tian

Brian R. Pettit

Gerald Fetterly, Jr.

The Science and Medical Advisory Team at Canget BioTekpharma plays a crucial role in guiding the development of innovative cancer-targeting therapies. Comprising experts in drug consulting and scientific research, the team advises on clinical trial designs, ensures compliance with regulatory standards, and provides insights on emerging scientific trends to optimize the efficacy and safety of anticancer agents. Their expertise helps bridge the gap between cutting-edge research and practical medical applications, contributing to the advancement of cancer treatment.

Science and Medical Advisory Team

The Leadership Team at Canget BioTekpharma is responsible for setting strategic direction and overseeing the development of innovative cancer-targeting therapies. Comprised of key executives, including the Chief Medical Officer and Chief Scientific Officer, the team ensures that the company's research aligns with its mission to create effective anticancer agents that minimize toxicity to healthy tissue. Through collaboration and decision-making, they drive the company’s vision and operational excellence in the biopharma sector.

Leadership Team

Canget BioTekpharma

Org chart

Board & advisors

Teams

Science and Medical Advisory Team

Leadership Team

Offices

Canget BioTekpharma

Org chart

Board & advisors

Teams

Science and Medical Advisory Team

Leadership Team

Offices

Related companies